P

Poolbeg Pharma PLC
LSE:POLB

Watchlist Manager
Poolbeg Pharma PLC
LSE:POLB
Watchlist
Price: 7.75 GBX 1.97% Market Closed
Market Cap: 38.8m GBX
Have any thoughts about
Poolbeg Pharma PLC?
Write Note

Poolbeg Pharma PLC
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Poolbeg Pharma PLC
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
P
Poolbeg Pharma PLC
LSE:POLB
Other Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Other Receivables
ÂŁ519m
CAGR 3-Years
-5%
CAGR 5-Years
23%
CAGR 10-Years
16%
AstraZeneca PLC
LSE:AZN
Other Receivables
$1.6B
CAGR 3-Years
48%
CAGR 5-Years
45%
CAGR 10-Years
16%
Verona Pharma PLC
NASDAQ:VRNA
Other Receivables
$5.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Other Receivables
$28m
CAGR 3-Years
-31%
CAGR 5-Years
-20%
CAGR 10-Years
8%
Dechra Pharmaceuticals PLC
LSE:DPH
Other Receivables
ÂŁ14.3m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Poolbeg Pharma PLC
Glance View

Market Cap
38.8m GBX
Industry
Pharmaceuticals

Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm is focused on targeting the medical needs to treat and prevent infectious disease. The firm's portfolio includes POLB 001, Vaccine Discovery Platform, PredictViral Biomarker Platform, and disease progression data and bio banks. The firm's lead product pipeline candidate is POLB 001. POLB 001 is a Phase II ready p38 mitogen-activated protein kinase (MAPK) inhibitor that reduces harmful inflammation (cytokine storm) in patients with severe influenza. POLB 001 is a repositioned small molecule immunomodulator for severe influenza. The firm is developing a PredictViral biomarker platform, which is used to identify those at risk of developing severe disease. The Vaccine Discovery Platform is a platform used to identify vaccine candidates by isolating protective elements of the naturally occurring immune response.

POLB Intrinsic Value
2.43 GBX
Overvaluation 69%
Intrinsic Value
Price
P

See Also

Back to Top